Literature DB >> 1713409

Class I and class II HLA antigens in a homogeneous Argentinian population with Whipple's disease: lack of association with HLA-B 27.

J C Bai1, A H Mota, E Mauriño, S Niveloni, F Grossman, L A Boerr, L Fainboim.   

Abstract

The prevalence of class I and class II HLA antigen was analyzed in 14 patients (12 males, two females) with Whipple's disease, diagnosed an average of 9.7 yr (range 6 months to 25 yr) before the typing. They were compared with 174 healthy control subjects of the same geographic area in Argentina. Class I antigens (locus A, B, C) were studied by lymphocytotoxic test, and class II antigens (locus DR, DQ) were detected by the double immunofluorescence technique. HLA-B27 was positive in one patient (7.7%) and in 4% of the control population. No significant association was found with the antigens tested. We observed no difference in the clinical picture or in the frequency of arthralgias, compared with those reported in the literature. Our data suggest that there is no conclusive proof of an association between HLA-B27 and Whipple's disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713409

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

Review 1.  Toward a new understanding of Whipple's disease.

Authors:  M C Flemmer; R W Flenner
Journal:  Curr Gastroenterol Rep       Date:  2000-08

Review 2.  Whipple's disease and "Tropheryma whippelii".

Authors:  F Dutly; M Altwegg
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

3.  Whipple's Disease.

Authors:  Klaus Mönkemüller; Lucía C Fry; Steffen Rickes; Peter Malfertheiner
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.725

4.  Reversible pulmonary hypertension in Whipple disease: a case report with clinicopathological implications, and literature review.

Authors:  Pamela L Lyle; Robert D Weber; Javier Bogarin; Tobias Kircher
Journal:  BMJ Case Rep       Date:  2009-05-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.